Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Department of Clinical Neurosciences, University of Cambridge, Cambridge. UK/NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London (UCL) Institute of Neurology, London. UK/Clinical Outcomes Research (CORe) Unit, The University of Melbourne, Melbourne, VIC, Australia.
Mult Scler. 2024 Jul;30(8):1066-1071. doi: 10.1177/13524585241233177. Epub 2024 Mar 1.
The Cambridge Centre for Myelin Repair One (CCMR-One) trial showed that 6 months of bexarotene reduces visual evoked potential (VEP) latency in people with relapsing-remitting multiple sclerosis (MS). In a single-centre follow-up study of these participants, we re-examined full-field VEP and clinical assessments. Twenty participants (12 bexarotene and 8 placebo) were seen on average 27 months after their trial involvement. In an analysis of all eyes with recordable signal (24 bexarotene and 14 placebo), the adjusted bexarotene-placebo treatment difference in P100 latency was -7.79 (95% confidence interval (CI) = -14.76, -0.82) ms, = 0.044. We conclude that there were durable improvements in VEP latency, suggesting long-term benefits from exposure to a remyelinating drug.
剑桥髓鞘修复中心一号（CCMR-One）试验表明，6 个月的贝沙罗汀可降低复发缓解型多发性硬化症（MS）患者的视觉诱发电位（VEP）潜伏期。在这些参与者的一项单中心随访研究中，我们重新检查了全视野 VEP 和临床评估。在试验参与平均 27 个月后，20 名参与者（12 名接受贝沙罗汀治疗，8 名接受安慰剂治疗）接受了检查。在对所有可记录信号的眼睛（24 名接受贝沙罗汀治疗，14 名接受安慰剂治疗）进行分析后，调整后的贝沙罗汀与安慰剂治疗 P100 潜伏期差值为-7.79（95%置信区间（CI）为-14.76，-0.82）ms，=0.044。我们得出结论，VEP 潜伏期有持久改善，提示接触髓鞘修复药物有长期获益。
